PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Barton, Kelly L ^a,b   Misuraca, Katherine ^c   Cordero, Francisco ^a,b   Dobrikova, Elena ^a   Min, Hooney D ^a   Gromeier, Matthias ^a   Kirsch, David G ^a   Becher, Oren J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PALBOCICLIB; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; DRUG EFFICACY; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PONTINE GLIOMA; PROTEIN EXPRESSION; RADIOTHERAPY; RETINOBLASTOMA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; MICE; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-SIS; PYRIDINES; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84884854055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077639     Document Type: Article

References (24)

1. Hargrave D, Bartels U, Bouffet E, (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7: 241-248. doi:10.1016/S1470-2045(06)70615-5. PubMed: 16510333.
2. Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, et al. (2012) An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neuro Oncol 108: 29-35. doi:10.1007/s11060-011-0796-x. PubMed: 22231932.
3. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DCHarbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC (1999) Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869. doi:10.1016/S0092-8674(00)81519-6. PubMed: 10499802.
4. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, et al. (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29: 3999-4006. doi:10.1200/JCO.2011.35.5677. PubMed: 21931021.
5. Puget S, Philippe C, Bax DA, Job B, Varlet P, et al. (2012) Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLOS ONE 7: e30313. doi:10.1371/journal.pone.0030313. PubMed: 22389665.
6. Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, et al. (2011) Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol 14: 326-332. PubMed: 22064882.
7. Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, et al. (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28: 1337-1344. doi:10.1200/JCO.2009.25.5463. PubMed: 20142589.
8. Chan KM, Fang D, Gan H, Hashizume R, Yu C, et al. (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27: 985-990. doi:10.1101/gad.217778.113. PubMed: 23603901.
9. Becher OJ, Hambardzumyan D, Walker TR, Helmy K, Nazarian J, et al. (2010) Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 70: 2548-2557. doi:10.1158/0008-5472.CAN-09-2503. PubMed: 20197468.
10. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, et al. (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124: 439-447. doi:10.1007/s00401-012-0998-0. PubMed: 22661320.
11. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, et al. (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18: 568-576. doi:10.1158/1078-0432.CCR-11-0509. PubMed: 22090362.
12. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, et al. (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1427-1438. PubMed: 15542782.
13. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, et al. (2012) Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119: 4597-4607. doi:10.1182/blood-2011-10-388298. PubMed: 22383795.
14. Lundberg AS, Weinberg RA, (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761. PubMed: 9447971.
15. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, et al. (2011) A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20: 620-634. doi:10.1016/j.ccr.2011.10.001. PubMed: 22094256.
16. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28: 3061-3068. doi:10.1200/JCO.2009.26.7252. PubMed: 20479398.
17. Katsumi Y, Iehara T, Miyachi M, Yagyu S, Tsubai-Shimizu S, et al. (2011) Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun 413: 62-68. doi:10.1016/j.bbrc.2011.08.047. PubMed: 21871868.
18. Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, et al. (2012) p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 14: 870-881. doi:10.1093/neuonc/nos114. PubMed: 22711607.
19. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, et al. (2012) Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A 109: 8710-8715. doi:10.1073/pnas.1117255109. PubMed: 22586120.
20. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, et al. (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70: 3228-3238. doi:10.1158/1538-7445.AM10-3228. PubMed: 20354191.
21. Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, et al. (2010) Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A 107: 11501-11506. doi:10.1073/pnas.1001613107. PubMed: 20534551.
22. Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, et al. (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340: 857-861. doi:10.1126/science.1232245. PubMed: 23539183.
23. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63. doi:10.1016/0022-1759(83)90303-4. PubMed: 6606682.
24. Newton J, Oldham M, Thomas A, Li Y, Adamovics J, et al. (2011) Commissioning a small-field biological irradiator using point, 2D, and 3D dosimetry techniques. Med Phys 38: 6754-6762. doi:10.1118/1.3663675. PubMed: 22149857.